GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Equity-to-Asset

G.Barekat Pharm (XTEH:BRKT1) Equity-to-Asset : 0.14 (As of Mar. 2017)


View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. G.Barekat Pharm's Total Stockholders Equity for the quarter that ended in Mar. 2017 was IRR5,003,506 Mil. G.Barekat Pharm's Total Assets for the quarter that ended in Mar. 2017 was IRR34,818,314 Mil. Therefore, G.Barekat Pharm's Equity to Asset Ratio for the quarter that ended in Mar. 2017 was 0.14.

The historical rank and industry rank for G.Barekat Pharm's Equity-to-Asset or its related term are showing as below:

XTEH:BRKT1's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

G.Barekat Pharm Equity-to-Asset Historical Data

The historical data trend for G.Barekat Pharm's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Equity-to-Asset Chart

G.Barekat Pharm Annual Data
Trend Mar16 Mar17
Equity-to-Asset
- 0.14

G.Barekat Pharm Semi-Annual Data
Mar16 Mar17
Equity-to-Asset - 0.14

Competitive Comparison of G.Barekat Pharm's Equity-to-Asset

For the Biotechnology subindustry, G.Barekat Pharm's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


G.Barekat Pharm's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G.Barekat Pharm's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where G.Barekat Pharm's Equity-to-Asset falls into.



G.Barekat Pharm Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

G.Barekat Pharm's Equity to Asset Ratio for the fiscal year that ended in Mar. 2017 is calculated as

Equity to Asset (A: Mar. 2017 )=Total Stockholders Equity/Total Assets
=5003506/34818314
=0.14

G.Barekat Pharm's Equity to Asset Ratio for the quarter that ended in Mar. 2017 is calculated as

Equity to Asset (Q: Mar. 2017 )=Total Stockholders Equity/Total Assets
=5003506/34818314
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


G.Barekat Pharm  (XTEH:BRKT1) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


G.Barekat Pharm Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


G.Barekat Pharm (XTEH:BRKT1) Business Description

Traded in Other Exchanges
N/A
Address
No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN
G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines